



ASSTON PHARMACEUTICALS LIMITED
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)

To,
BSE Limited
Listing / Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Date: 02-03-2026

BSE Scrip Code: -544445

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Respected Stakeholders,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform the Stock Exchanges that the Board of Directors of the Company, on the recommendation of the Audit Committee and in due compliance with the provisions of Section 175 of the Companies Act, 2013 and the rules made thereunder, has accorded its approval by way of a resolution passed by circulation for the appointment of M/s Panchal S K and Associates (Peer Review Certificate No. 018089 and Firm Registration No. 145989W) as the Statutory Auditors of the Company, subject to the approval of the shareholders of the Company at the ensuing General Meeting.

The appointment has been made after due consideration of the firm's professional standing, eligibility, and credentials, in accordance with the applicable provisions of the Companies Act, 2013 and the rules framed thereunder.

The disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are enclosed herewith as Annexure A and form an integral part of this intimation.”

In compliance with the provisions of Section 175 of the Companies Act, 2013, read with the rules made thereunder and other applicable laws for the time being in force, the delay in submission to the Exchange occurred due to the Company receiving the requisite approval of the majority of Directors on Friday, 27th February, 2026, after business hours. Thereafter, Saturday and Sunday, being non-working days, fell on 28th February, 2026, and 01st March, 2026, respectively. Accordingly, the said approval was intimated to the Exchange on the immediately succeeding working day, i.e., Monday, 02nd March, 2026.

Kindly take the above on record.

This disclosure complies with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For Asston Pharmaceuticals Limited
Rishi Upadhaya
Company Secretary and Compliance Officer
A74324

CIN: U24304MH2019PLC324187

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi
Mumbai, Thane, Maharashtra, 400614, India
Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com
Web: www.asstonpharmaceuticals.com



ASSTON PHARMACEUTICALS LIMITED
(FORMERLY KNOWN AS ASSTON PHARMACEUTICALS PRIVATE LIMITED)

Annexure-A

The details, as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is as follows:

1	Name of the statutory auditor:	M/s Panchal S K and Associates, Peer Review Certificate No. 018089, Firm Registration No. 145989W.
2	Reason for Change:	Appointment in Casual Vacancy
3	Date of appointment and terms of appointment:	27 th February, 2026, by passing a resolution by circulation by the Board of Directors of the Company
4	Brief profile:	M/s. Panchal S K & Associates (est. 2017, ICAI Reg. No. 145989W) is led by founder partner Swati Panchal, a member of ICAI since 2012. It is a team of young and dynamic professionals. Further, their experience spans SMEs to large corporates across various industries, reflecting expertise and commitment to delivering quality professional services.
5	Disclosure of relationship with directors:	Not applicable.

CIN: U24304MH2019PLC324187

Reg. Office- 4th Floor Office No A-431 Balaji Bhavan, Plot No 42a Sector-11 CBD Belapur, Navi
Mumbai, Thane, Maharashtra, 400614, India

Phone No.: 022-49731419 / 49731411, Email id: aston.tech14@gmail.com

Web: www.asstonpharmaceuticals.com